KR20240038028A - Ct45에 특이적으로 결합하는 항원 결합 단백질 - Google Patents

Ct45에 특이적으로 결합하는 항원 결합 단백질 Download PDF

Info

Publication number
KR20240038028A
KR20240038028A KR1020247005786A KR20247005786A KR20240038028A KR 20240038028 A KR20240038028 A KR 20240038028A KR 1020247005786 A KR1020247005786 A KR 1020247005786A KR 20247005786 A KR20247005786 A KR 20247005786A KR 20240038028 A KR20240038028 A KR 20240038028A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
antigen binding
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247005786A
Other languages
English (en)
Korean (ko)
Inventor
사라 유세프
파비안 브룬크
안드레아스 모리츠
세바스티안 붕크
클라우디아 바그너
도미니크 모이러
펠릭스 운페르도르벤
Original Assignee
이매틱스 바이오테크놀로지스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이매틱스 바이오테크놀로지스 게엠베하 filed Critical 이매틱스 바이오테크놀로지스 게엠베하
Publication of KR20240038028A publication Critical patent/KR20240038028A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G01N33/57496—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020247005786A 2021-07-27 2022-07-27 Ct45에 특이적으로 결합하는 항원 결합 단백질 Pending KR20240038028A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163203582P 2021-07-27 2021-07-27
US63/203,582 2021-07-27
EP21188018.2 2021-07-27
EP21188018 2021-07-27
US202263335399P 2022-04-27 2022-04-27
US63/335,399 2022-04-27
PCT/EP2022/071104 WO2023006828A1 (en) 2021-07-27 2022-07-27 Antigen binding proteins specifically binding ct45

Publications (1)

Publication Number Publication Date
KR20240038028A true KR20240038028A (ko) 2024-03-22

Family

ID=82939905

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247005786A Pending KR20240038028A (ko) 2021-07-27 2022-07-27 Ct45에 특이적으로 결합하는 항원 결합 단백질

Country Status (13)

Country Link
US (2) US12209137B2 (https=)
EP (1) EP4377330A1 (https=)
JP (1) JP2024529467A (https=)
KR (1) KR20240038028A (https=)
AU (1) AU2022318257A1 (https=)
CA (1) CA3226437A1 (https=)
CL (1) CL2024000207A1 (https=)
CO (1) CO2024000677A2 (https=)
IL (1) IL310374A (https=)
MX (1) MX2024001179A (https=)
PE (1) PE20240779A1 (https=)
TW (1) TW202321277A (https=)
WO (1) WO2023006828A1 (https=)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
ES2203782T3 (es) 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
JP4972264B2 (ja) 1999-12-06 2012-07-11 ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 高親和性ｔｃｒタンパク質および方法
DE10225139A1 (de) 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
US7751825B2 (en) 2002-06-27 2010-07-06 Qualcomm Incorporated Controlling geographic location information of devices operating in wireless communication systems
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
JP2007519910A (ja) 2004-01-28 2007-07-19 イマティクス バイオテクノロジーズ ゲーエムベーハー 腫瘍関連ペプチドの同定および定量方法
CA2579558A1 (en) * 2004-09-08 2006-03-16 Ludwig Institute For Cancer Research Cancer-testis antigens
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
AU2013295652B2 (en) 2012-07-27 2018-02-08 The Board Of Trustees Of The University Of Illinois Engineering T-cell receptors
SI2932264T1 (sl) * 2012-12-14 2019-05-31 Biontech Rna Pharmaceuticals Gmbh Novi MHC-neodvisni, s tumorjem povezani antigeni
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
US11261223B2 (en) 2016-05-11 2022-03-01 The University Of Chicago Methods of treating cancers with CT45 targeted therapies
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
SG11202000025SA (en) 2017-07-14 2020-02-27 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
US20220175899A1 (en) 2019-04-11 2022-06-09 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer

Also Published As

Publication number Publication date
TW202321277A (zh) 2023-06-01
JP2024529467A (ja) 2024-08-06
MX2024001179A (es) 2024-02-27
US20250122302A1 (en) 2025-04-17
US20230057987A1 (en) 2023-02-23
CO2024000677A2 (es) 2024-05-10
CL2024000207A1 (es) 2024-06-14
AU2022318257A1 (en) 2024-02-08
EP4377330A1 (en) 2024-06-05
IL310374A (en) 2024-03-01
US12209137B2 (en) 2025-01-28
CA3226437A1 (en) 2023-02-02
WO2023006828A1 (en) 2023-02-02
PE20240779A1 (es) 2024-04-17

Similar Documents

Publication Publication Date Title
CN110730908B (zh) 表达前列腺特异性膜抗原（psma）或其修饰形式的工程化细胞及相关方法
CN105452288B (zh) 抗人乳头瘤病毒16 e6 t细胞受体
EP3689900B1 (en) Expression vectors for anti-human papillomavirus 16 e7 t cell receptors
JP2021191265A (ja) Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体
US20090042798A1 (en) T cell receptors and related materials and methods of use
TW201831505A (zh) 針對ａｘｌ或ｒｏｒ２之嵌合抗原受體及其使用之方法
KR20190026740A (ko) 입양 세포 치료법을 이용한 b 세포 악성종양의 치료 방법
CN112533943B (zh) Il-13/il-4超级因子：免疫细胞靶向性构建体及其使用方法
US20240123070A1 (en) Epitope peptide of ras g13d mutant and t cell receptor recognizing ras g13d mutant
KR20230010228A (ko) 자연 살해 세포를 표적으로 하는 키메라 항원 수용체 (cars)
TW202140535A (zh) 針對含有g12v突變之ras之hla第i類限制性t細胞受體
US20230272038A1 (en) Hla class ii-restricted drb t cell receptors against ras with g12d mutation
EP4253410A1 (en) Ras mutant epitope peptide and t cell receptor recognizing ras mutant
TWI900647B (zh) 識別p53中r273c或y220c突變的t細胞受體
US12209137B2 (en) Antigen binding proteins specifically binding CT45
CN117980324A (zh) 特异性结合ct45的抗原结合蛋白
Wang et al. Peptide-Specific CARs Recognize WT1 Promiscuously Presented by Diverse HLA Class II Alleles
WO2025021979A1 (en) Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
US20250213687A1 (en) Therapeutic t cell product
WO2026033136A1 (en) Advanced treatment modalities for anti-prame tcr-engineered immune cells
HK40030123A (en) Expression vectors for anti-human papillomavirus 16 e7 t cell receptors
HK40030123B (en) Expression vectors for anti-human papillomavirus 16 e7 t cell receptors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000